about
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
P50
description
wetenschapper
@nl
name
B Gamberi
@en
B Gamberi
@nl
type
label
B Gamberi
@en
B Gamberi
@nl
prefLabel
B Gamberi
@en
B Gamberi
@nl
P31
P496
0000-0003-3616-5838